✦ LIBER ✦

M1 Muscarinic Agonists as Potential Disease-Modifying Agents in Alzheimer's Disease: Rationale and Perspectives

✍ Scribed by A. FISHER; D.M. MICHAELSON; R. BRANDEIS; R. HARING; S. CHAPMAN; Z. PITTEL

Book ID: 111396690
Publisher: John Wiley and Sons
Year: 2006
Tongue: English
Weight: 203 KB
Volume: 920
Category: Article
ISSN: 0890-6564
DOI: 10.1111/j.1749-6632.2000.tb06941.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

M1 muscarinic agonists: Their potential

M1 muscarinic agonists: Their potential in treatment and as disease-modifying agents in Alzheimer's disease

✍ Abraham Fisher 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 108 KB 👁 1 views

Cholinergic treatments with emphasis on

Cholinergic treatments with emphasis on M1 muscarinic agonists as potential disease-modifying agents for Alzheimer’s disease

✍ Abraham Fisher 📂 Article 📅 2008 🏛 Springer-Verlag 🌐 English ⚖ 113 KB

M1muscarinic agonists can modulate some

M1muscarinic agonists can modulate some of the hallmarks in Alzheimer’s disease

✍ Abraham Fisher; Zipora Pittel; Rachel Haring; Nira Bar-Ner; Michal Kliger-Spatz; 📂 Article 📅 2003 🏛 Humana Press Inc 🌐 English ⚖ 332 KB

Pharmacological Mechanisms in Alzheimer'

Pharmacological Mechanisms in Alzheimer's Therapeutics || M1 Muscarinic Agonists: A Comprehensive Therapy Against Major Hallmarks of Alzheimer's Disease

✍ Cuello, A. Claudio 📂 Article 📅 2007 🏛 Springer New York 🌐 English ⚖ 156 KB

The need for effective therapy to treat Alzheimer’s disease is greater than ever, but there is still no drug therapy that can stop or reverse the progression of the disease. There is, however, a great deal of anticipation over the imminent development of effective therapies as a result of the identi

Rationale for the use of dopamine agonis

Rationale for the use of dopamine agonists as neuroprotective agents in Parkinson's disease

✍ Anthony H. V. Schapira; C. Warren Olanow 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 112 KB 👁 2 views

Development of M1 subtype selective musc

Development of M1 subtype selective muscarinic agonists for Alzheimer's disease: Translation of in vitro selectivity into in vivo efficacy

✍ R.D. Schwarz; M.J. Callahan; R.E. Davis; J.C. Jaen; H. Tecle 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 131 KB 👁 2 views

Clinical trials in Alzheimer's disease (AD) with first generation muscarinic agonists (e.g., arecoline, oxotremorine, pilocarpine) produced inconsistent results due to poor pharmacokinetic properties and a lack of separation between central and peripheral activities observed with these compounds. Se